We previously reported a series of antibodies, in fragment antigen binding domain (Fab) formats, selected from a human non-immune phage library, directed against the internal trimeric coiled-coil of the N-heptad repeat (N-HR) of HIV-1 gp41. Broadly neutralizing antibodies from that series bind to both the fully exposed N-HR trimer, representing the pre-hairpin intermediate state of gp41, and to partially-exposed N-HR helices within the context of the gp41 six-helix bundle. While the affinities of the Fabs for pre-hairpin intermediate mimetics vary by only 2 to 20-fold between neutralizing and non-neutralizing antibodies, differences in inhibition of viral entry exceed three orders of magnitude. Here we compare the binding of neutralizing (8...
Abstract Background The CD4-induced (CD4i) epitopes in gp120 includes the co-receptor binding site, ...
The identification of the determinants of sensitivity and resistance to broadly neutralizing antibod...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
<div><p>A series of mini-antibodies (monovalent and bivalent Fabs) targeting the conserved internal ...
A series of mini-antibodies (monovalent and bivalent Fabs) targeting the conserved internal trimeric...
AbstractFollowing CD4 receptor binding to the HIV-1 envelope spike (Env), the conserved N-heptad rep...
HIV neutralizing antibodies (nAbs) represent an important tool in view of prophylactic and therapeut...
<div><p>HIV neutralizing antibodies (nAbs) represent an important tool in view of prophylactic and t...
AbstractPreviously we reported a broadly HIV-1 neutralizing mini-antibody (Fab 3674) of modest poten...
HIV neutralizing antibodies (nAbs) represent an important tool in view of prophylactic and therapeut...
A monoclonal Fab (Fab 3674) selected from a human nonimmune phage library by panning against the chi...
<div><p>The broadly neutralizing HIV-1 antibody 2F5 recognizes an epitope in the gp41 membrane proxi...
Antibodies m66.6 and 2F5 are the only effective humanHIV-1-neutralizing antibodies reported thus far...
SummaryBroadly neutralizing monoclonal antibodies to HIV-1 are rare but invaluable for vaccine desig...
The identification of the determinants of sensitivity and resistance to broadly neutralizing antibod...
Abstract Background The CD4-induced (CD4i) epitopes in gp120 includes the co-receptor binding site, ...
The identification of the determinants of sensitivity and resistance to broadly neutralizing antibod...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
<div><p>A series of mini-antibodies (monovalent and bivalent Fabs) targeting the conserved internal ...
A series of mini-antibodies (monovalent and bivalent Fabs) targeting the conserved internal trimeric...
AbstractFollowing CD4 receptor binding to the HIV-1 envelope spike (Env), the conserved N-heptad rep...
HIV neutralizing antibodies (nAbs) represent an important tool in view of prophylactic and therapeut...
<div><p>HIV neutralizing antibodies (nAbs) represent an important tool in view of prophylactic and t...
AbstractPreviously we reported a broadly HIV-1 neutralizing mini-antibody (Fab 3674) of modest poten...
HIV neutralizing antibodies (nAbs) represent an important tool in view of prophylactic and therapeut...
A monoclonal Fab (Fab 3674) selected from a human nonimmune phage library by panning against the chi...
<div><p>The broadly neutralizing HIV-1 antibody 2F5 recognizes an epitope in the gp41 membrane proxi...
Antibodies m66.6 and 2F5 are the only effective humanHIV-1-neutralizing antibodies reported thus far...
SummaryBroadly neutralizing monoclonal antibodies to HIV-1 are rare but invaluable for vaccine desig...
The identification of the determinants of sensitivity and resistance to broadly neutralizing antibod...
Abstract Background The CD4-induced (CD4i) epitopes in gp120 includes the co-receptor binding site, ...
The identification of the determinants of sensitivity and resistance to broadly neutralizing antibod...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...